BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kardigan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Kardigan's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07511361-531@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tonlamarsen: Phase 2 readout est. (NCT07511361)
DESCRIPTION:Tonlamarsen\, phase 2\, Hypertension.\nStudy: Study of Efficacy
  and Safety of Tonlamarsen in Participants With a Recent Hospitalization a
 nd a Concurrent Episode of Acute Severe Hypertension\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tonlamarsen#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07511361
URL:https://assetmemo.bio/drug/tonlamarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210723-596@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Danicamtiv: Phase 2/3 readout est. (NCT07210723)
DESCRIPTION:Danicamtiv\, phase 2/3.\nStudy: A Study of the Efficacy and Saf
 ety of Danicamtiv in Participants With Symptomatic Genetic and Familial Di
 lated Cardiomyopathy\nEstimated primary completion: September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/danicamtiv#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07210723
URL:https://assetmemo.bio/drug/danicamtiv#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771465-596@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Danicamtiv: Phase 3 readout est. (NCT07771465)
DESCRIPTION:Danicamtiv\, phase 3.\nStudy: A Study of the Long-term Safety a
 nd Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial 
 Dilated Cardiomyopathy\nEstimated primary completion: November 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/danicamtiv#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07771465
URL:https://assetmemo.bio/drug/danicamtiv#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
